Yes, kratom and Suboxone interact in multiple ways. Both substances act on the same opioid receptors in the brain, and kratom’s main alkaloid strongly inhibits a liver enzyme involved in processing buprenorphine (the active opioid in Suboxone). The combination creates risks ranging from unpredictable drug levels to compounded sedation and potential liver stress.
How Both Substances Act on Opioid Receptors
Kratom contains two key alkaloids that target the mu-opioid receptor, the same receptor that buprenorphine binds to. The more abundant one, mitragynine, actually acts as an antagonist at that receptor, meaning it blocks activation rather than triggering it. The less abundant but far more potent one, 7-hydroxymitragynine, is a partial agonist with about nine times stronger binding affinity than mitragynine.
Buprenorphine, the opioid component of Suboxone, is also a partial agonist at the mu-opioid receptor, but it binds with considerably greater strength than either kratom alkaloid. Buprenorphine’s binding affinity is roughly 10 to 90 times stronger than kratom’s alkaloids, depending on which one you compare. This means buprenorphine can effectively push kratom compounds off the receptor and take their place.
Because both substances are partial agonists or antagonists rather than full agonists, combining them doesn’t produce the same additive high you’d get from stacking two full opioids. Instead, the interaction is more complex: the two compete for the same receptor sites, and buprenorphine generally wins that competition due to its stronger grip.
The Enzyme Problem in Your Liver
Beyond receptor competition, kratom creates a significant drug interaction at the metabolic level. Mitragynine is a strong inhibitor of CYP2D6, one of the liver enzymes responsible for breaking down many medications. Its inhibitory potency against CYP2D6 is high enough to be clinically relevant at typical kratom doses. Mitragynine also inhibits CYP3A, another major drug-processing enzyme, with roughly a sevenfold increase in inhibitory strength over time as the compound accumulates in liver tissue.
Buprenorphine is processed through CYP3A4. If kratom is slowing down that enzyme, buprenorphine could build up to higher-than-expected levels in your bloodstream. This raises the possibility of exaggerated sedation, dizziness, and respiratory effects that neither substance would produce alone at those doses. One documented kratom-related death involved toxic levels of quetiapine, a medication processed by CYP3A, in a person who was not suspected of taking an overdose amount. The elevated drug levels were attributed to kratom’s enzyme-blocking effects.
Precipitated Withdrawal Risk
People who use kratom regularly and then start Suboxone sometimes worry about precipitated withdrawal, the rapid onset of intense withdrawal symptoms that occurs when a stronger-binding opioid displaces a weaker one from receptors. This is a well-known risk when starting buprenorphine while conventional opioids are still active in the body.
With kratom, the picture is somewhat different. Because buprenorphine has much higher binding affinity than kratom alkaloids, it will displace them from opioid receptors. However, since buprenorphine itself provides partial opioid activation, it typically alleviates withdrawal rather than worsening it. In published case reports, patients who started buprenorphine-naloxone 12 to 14 hours after their last kratom dose experienced relief from withdrawal symptoms rather than precipitated withdrawal. One patient began a low dose and titrated up over the first 24 hours, while another started at a higher dose through home induction, and both tolerated the transition well.
That said, the naloxone component in Suboxone is specifically included to discourage misuse. If Suboxone is taken in unintended ways, naloxone becomes more active and can trigger withdrawal in anyone with opioid dependence, including kratom dependence.
Liver Damage Concerns
Kratom use has been linked to rare but sometimes severe liver injury. In one documented case, a patient developed liver enzyme levels four to ten times the upper limit of normal while using kratom. When the same patient was hospitalized months later with similar lab findings, they were still using kratom but had stopped all other suspected medications, strengthening the case that kratom was the cause.
Buprenorphine can also affect the liver, though significant injury is uncommon at standard doses. The concern with combining the two is additive liver stress. If kratom is already irritating liver tissue and simultaneously blocking the enzymes that process buprenorphine, the liver faces a compounded burden. This is especially relevant for people with pre-existing liver conditions or those taking other medications that tax liver function.
Seizure Reports
There are case reports linking kratom use to seizures, including at least one involving a patient who was also taking buprenorphine-naloxone. In that case, a 43-year-old man who had been drinking kratom tea four times daily for over three years experienced a generalized seizure. After stopping kratom and continuing buprenorphine-naloxone, he remained seizure-free. A separate case documented a newborn having seizures within 24 hours of birth after the mother used kratom during pregnancy. While these are individual reports and don’t prove kratom alone caused the seizures, they suggest the combination deserves caution, particularly in people with a history of seizure disorders.
Using Both at the Same Time
Some people use kratom while already taking Suboxone, either because they’re trying to supplement the effects or because they started kratom before beginning medication-assisted treatment. From a pharmacological standpoint, this is problematic for several reasons. Buprenorphine’s strong receptor binding means kratom’s opioid effects are largely blocked, so you’re unlikely to feel the kratom working as expected. Meanwhile, kratom’s enzyme inhibition could cause buprenorphine levels to rise unpredictably. You also get the combined sedation, respiratory effects, and liver strain without a proportional increase in therapeutic benefit.
The compounded drowsiness and breathing suppression are the most immediate safety concerns. Both substances cause sedation independently, and slowed CYP3A metabolism of buprenorphine could amplify that effect beyond what either dose would produce on its own. Adding alcohol or benzodiazepines to this mix further increases the danger.
Transitioning From Kratom to Suboxone
For people looking to stop kratom and begin Suboxone treatment, the available evidence suggests a waiting period of roughly 12 to 14 hours after the last kratom dose before starting buprenorphine-naloxone. This allows kratom levels to drop enough that the transition goes smoothly. In documented cases, patients who followed this timeline experienced relief from kratom withdrawal symptoms including pain, restlessness, and cravings once buprenorphine took effect.
The key difference from transitioning off traditional opioids is that kratom’s weaker receptor binding makes precipitated withdrawal less likely. Buprenorphine can step in more easily because it doesn’t have to displace a high-affinity full agonist. Still, the timing matters, and individual responses vary based on how much kratom was being used, how frequently, and for how long.